Connective Tissue Diseases
A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
Subtype terms (26)
More specific conditions that are subtypes of Connective Tissue Diseases in the MeSH hierarchy.
- Anetoderma
- Cartilage Diseases
33 drugs (9 approved, 24 experimental)
- Cellulitis
33 drugs (29 approved, 4 experimental)
- Collagen Diseases
4 drugs (3 approved, 1 experimental)
- Cutis Laxa
2 drugs experimental
- Dermatomyositis
73 drugs (43 approved, 30 experimental)
- Dupuytren Contracture
13 drugs (10 approved, 3 experimental)
- Fibromatosis, Plantar
1 drug approved
- Homocystinuria
7 drugs (3 approved, 4 experimental)
- Lipedema
3 drugs (1 approved, 2 experimental)
- Lupus Erythematosus, Cutaneous
41 drugs (15 approved, 26 experimental)
- Lupus Erythematosus, Systemic
362 drugs (137 approved, 225 experimental)
- Marfan Syndrome
9 drugs approved
- Mixed Connective Tissue Disease
5 drugs (3 approved, 2 experimental)
- Mucinoses
1 drug experimental
- Neoplasms, Connective Tissue
9 drugs (7 approved, 2 experimental)
- Noonan Syndrome
7 drugs approved
- Osteopoikilosis
- Panniculitis
2 drugs (1 approved, 1 experimental)
- Penile Induration
16 drugs (8 approved, 8 experimental)
- Pseudoxanthoma Elasticum
8 drugs (4 approved, 4 experimental)
- Rheumatic Diseases
59 drugs (41 approved, 18 experimental)
- Scleroderma, Localized
9 drugs (7 approved, 2 experimental)
- Scleroderma, Systemic
177 drugs (90 approved, 87 experimental)
- Undifferentiated Connective Tissue Diseases
4 drugs approved
- Weill-Marchesani Syndrome
Drugs by status
Approved for this indication (1)
Phase 4 trials (14)
Phase 3 trials (5)
Phase 2 trials (8)
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (16)
- AbbVie
- United Therapeutics
- Eli Lilly
- Pfizer
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- Johns Hopkins University
- University of Rochester
- Jiao Tong University
- Kerckoff clinic, Bad Nauheim, Germany
- University of Sao Paulo
- Department of Veteran Affairs
- Chinese Academy of Medical Sciences
- Narrows Institute for Biomedical Research
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (15)
- Covis
- Cumberland Pharmaceuticals
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Georgetown University
- Northwestern University
- University of Tennessee
- Wayne State University
- University of California, Los Angeles
- University of Cincinnati
- Vanderbilt University
- Medical University of South Carolina
- Icahn School of Medicine at Mount Sinai
- University of Alabama, Birmingham
- Leo Pharma
- University of Tennessee, Memphis
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (5)